Haldi (Turmeric)

<h3> Absolute Contraindications of Haldi (Turmeric) </h3> <h4> 1) Gallbladder obstruction / known gallstones (blocked bile ducts or symptomatic gallstones)</h4> <ul> <li>🟠</li> <li>Recommendation: Avoid therapeutic-dose turmeric supplements; small culinary use is usually OK, but check with your doctor if you have gallstones or biliary obstruction.</li> <li>Reasoning: Curcumin has choleretic and gallbladder-contracting effects; in people with existing stones or obstruction, stimulating gallbladder contraction can provoke pain or biliary colic and worsen obstruction.</li> <li>Scientific_Study_Title: The effect of curcumin and placebo on human gall-bladder function: an ultrasound study</li> <li>Scientific_Study_Authors: Laekeman G, et al. (authors as listed on PubMed entry)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/10102956/</li> <li>Scientific_Study_Excerpt: <p>In a randomized, double-blind, crossover study in healthy volunteers the authors measured gallbladder volumes by ultrasound after curcumin (20 mg) versus placebo and found statistically significant reductions in gallbladder volume after curcumin-percentage volume reduction reached ~29% at 2 hours-demonstrating curcumin’s ability to induce gallbladder contraction. The study supports the traditional choleretic use of turmeric but implies that in a person with obstructing gallstones this contraction could precipitate biliary pain or complications.</p> </li> </ul> <h4> 2) On strong oral anticoagulant or with active bleeding disorders (e.g., warfarin, vitamin K antagonists)</h4> <ul> <li>🩸</li> <li>Recommendation: Do not use turmeric supplements without clinician approval and close INR/bleeding-parameter monitoring; avoid if unstable anticoagulation or recent major bleeding.</li> <li>Reasoning: Turmeric/curcumin can potentiate anticoagulation (antiplatelet and pharmacokinetic effects) and case reports describe elevated INR/bleeding when combined with vitamin-K antagonists.</li> <li>Scientific_Study_Title: Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa)</li> <li>Scientific_Study_Authors: Lebreton A, et al. (as per PubMed entry)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25230280/</li> <li>Scientific_Study_Excerpt: <p>The authors report a clinical case where co-consumption of turmeric was temporally associated with elevation of the international normalized ratio (INR) in a patient on the vitamin K antagonist fluindione. Investigation suggested a probable herb-drug interaction; the report highlights the potential for turmeric to alter anticoagulant drug effects and recommends considering herbal exposure when unexpected INR changes occur.</p> </li> </ul> <h4> 3) Pregnancy (therapeutic/high-dose turmeric or curcumin supplements)</h4> <ul> <li>🤰</li> <li>Recommendation: Avoid medicinal-dose turmeric/curcumin supplements during pregnancy; culinary amounts in food are generally considered safe but check with your healthcare provider.</li> <li>Reasoning: Human safety data are limited; animal and mechanistic studies show dose-dependent effects on reproductive tissues and incomplete safety evidence means caution is advised.</li> <li>Scientific_Study_Title: Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications? (review)</li> <li>Scientific_Study_Authors: G. et al. (authors listed in PubMed review)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/33080891/</li> <li>Scientific_Study_Excerpt: <p>This review summarizes mostly animal and in vitro data on curcumin during pregnancy. It notes curcumin’s multiple molecular effects (anti-inflammatory, antioxidant, antiangiogenic) and emphasizes that evidence in pregnancy is fragmentary and inconsistent-some animal models show protective effects in specific conditions while others show cytotoxicity at higher concentrations. The authors conclude that clinical safety data are limited and further research is required, advising caution with medicinal doses in pregnant humans.</p> </li> </ul> <h4> 4) Known severe liver disease with active liver injury</h4> <ul> <li>🟣</li> <li>Recommendation: Avoid turmeric supplements if you have active drug-induced or severe liver disease unless supervised by a hepatologist; if using, monitor liver enzymes closely and stop if they rise.</li> <li>Reasoning: Although rare, turmeric/curcumin supplements have been reported to cause drug-induced liver injury (DILI) in susceptible individuals; formulations and dose matter.</li> <li>Scientific_Study_Title: Turmeric-Induced Hepatotoxicity: Report of 2 Cases</li> <li>Scientific_Study_Authors: Sohal A, Alhankawi D, Sandhu S, Chintanaboina J.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/34992472/</li> <li>Scientific_Study_Excerpt: <p>Two clinical cases are described in which patients developed laboratory and biopsy-confirmed drug-induced liver injury after consuming turmeric supplements; both subjects resolved after stopping the supplement. The report highlights that concentrated turmeric supplements (and products with enhanced absorption) have been associated with acute liver enzyme elevations and that clinicians should include herbal supplement use in medication reconciliation when evaluating liver injury.</p> </li> </ul> <h3> Relative Contraindications of Haldi (Turmeric) </h3> <h4> 1) Patients on calcineurin immunosuppressants (e.g., tacrolimus, cyclosporine) - caution</h4> <ul> <li>⚠️</li> <li>Recommendation: Avoid high-dose turmeric supplements; if considered, discuss with transplant team and monitor drug levels (tacrolimus/cyclosporine) closely.</li> <li>Reasoning: Curcumin can alter CYP3A/P-glycoprotein activity and case reports/animal data show turmeric may raise tacrolimus concentrations, risking nephrotoxicity.</li> <li>Scientific_Study_Title: Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report</li> <li>Scientific_Study_Authors: Nayeri A, Wu S, Adams E, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/28104136/</li> <li>Scientific_Study_Excerpt: <p>The case report describes a liver transplant patient with stable tacrolimus dosing who developed a marked rise in tacrolimus blood levels and acute nephrotoxicity after consuming high amounts of turmeric. Investigators implicated turmeric as the likely cause due to timing and lack of other explanations. The report underscores a possible herb-drug pharmacokinetic interaction via CYP3A/P-gp modulation and recommends monitoring in transplant recipients.</p> </li> </ul> <h4> 2) Patients on narrow-therapeutic-index CYP3A4 substrates (e.g., certain targeted cancer drugs, immunosuppressants) - caution</h4> <ul> <li>⚠️</li> <li>Recommendation: Avoid turmeric supplements or discuss with your oncologist/pharmacist; if used, monitor drug levels and effects carefully.</li> <li>Reasoning: Curcumin can modulate CYP3A4 and P-glycoprotein in vivo/in vitro, potentially increasing or decreasing levels of CYP3A4 substrates and altering effectiveness or toxicity.</li> <li>Scientific_Study_Title: Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies</li> <li>Scientific_Study_Authors: Hou Z, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25300360/</li> <li>Scientific_Study_Excerpt: <p>In rat models, oral curcumin coadministration significantly changed the pharmacokinetics of everolimus (a CYP3A4/P-gp substrate) by markedly decreasing its blood exposure, an effect attributed to activation of CYP3A4 by curcumin metabolites. The study demonstrates that curcumin’s net impact on drug-metabolizing enzymes may be complex and dose-dependent, implying caution when combining with sensitive CYP3A4 substrates.</p> </li> </ul> <h4> 3) People treated for diabetes with glucose-lowering drugs (relative caution)</h4> <ul> <li>🩺</li> <li>Recommendation: If you take insulin or oral hypoglycemics, discuss turmeric supplements with your clinician and monitor blood glucose frequently to avoid hypoglycemia.</li> <li>Reasoning: Multiple clinical trials show curcumin can lower fasting glucose and HbA1c; when combined with antidiabetic drugs, additive glucose-lowering may occur.</li> <li>Scientific_Study_Title: Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials</li> <li>Scientific_Study_Authors: Ashtary-Larky H, et al. (authors as indexed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/34331688/</li> <li>Scientific_Study_Excerpt: <p>This systematic review pooled randomized clinical trials and found curcumin supplementation was associated with significant reductions in fasting blood glucose and HbA1c in people with type 2 diabetes, particularly with longer supplementation (≥12 weeks). The evidence suggests curcumin has clinically relevant glucose-lowering effects and could potentiate other hypoglycemic therapies.</p> </li> </ul>